niacinamide has been researched along with Head and Neck Neoplasms in 39 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage IV metastatic melanoma and no previous systemic therapies apart from adjuvant immunotherapy received Peg-IFN-α2b 3 μg/kg once per week, and sorafenib 400-mg b." | 9.15 | Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. ( Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T, 2011) |
| "Patients with stage IV metastatic melanoma and no previous systemic therapies apart from adjuvant immunotherapy received Peg-IFN-α2b 3 μg/kg once per week, and sorafenib 400-mg b." | 5.15 | Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. ( Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T, 2011) |
| ""ARCON" combines accelerated radiotherapy to counteract tumor repopulation with carbogen breathing and nicotinamide to reduce chronic and acute hypoxia." | 5.10 | ARCON: experience in 215 patients with advanced head-and-neck cancer. ( Bruaset, I; Kaanders, JH; Marres, HA; Merkx, MA; Pop, LA; van den Hoogen, FJ; van der Kogel, AJ, 2002) |
| "Sorafenib was administered orally at 400 mg bid on a continuous basis." | 2.82 | Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer. ( Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M, 2016) |
| "Sorafenib was administered orally at 400 mg twice daily on a continuous basis in 28-day cycles." | 2.75 | Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. ( Guaglianone, PP; Huang, CH; LeBlanc, M; Moon, J; Urba, SG; Williamson, SK; Wolf, GT, 2010) |
| "Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities." | 2.73 | Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. ( Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E, 2007) |
| "Full pharmacokinetic profiles of nicotinamide concentrations in plasma were analyzed repeatedly in 15 patients to determine the inter- and intra-patient variability in peak plasma concentrations and the optimum times for administering nicotinamide as a radiosensitizer." | 2.69 | Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. ( Bernier, J; Bieri, S; Bolla, M; Denekamp, J; Dennis, MF; Hagen, F; Kocagöncü, O; Rojas, A; Stratford, MR, 1998) |
| "Between March 1991 and October 1993, 49 patients with inoperable head and neck carcinoma were randomly assigned to receive either radiation therapy alone (group A) or radiotherapy combined with simultaneous application of Mitomycin C and Bleomycin (group B)." | 2.68 | Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report. ( Budihna, M; Furlan, L; Lesnicar, H; Rudolf, Z; Smid, L; Soba, E; Zakotnik, B; Zargi, M, 1995) |
| "Radioresistance is a common feature of head and neck squamous cell carcinoma (HNSCC)." | 1.46 | Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. ( Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W, 2017) |
| "In head and neck squamous cell carcinoma (HNSCC), the role of sprouty2 in tumorigenesis and clinical implication remains elusive." | 1.42 | Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. ( Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL, 2015) |
| "Head and neck squamous cell carcinoma (HNSCC) is an aggressive epithelial malignancy." | 1.42 | Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC. ( Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C, 2015) |
| "Sorafenib was administered orally at 400 mg twice daily on a continuous basis in 28-day cycles to eligible patients." | 1.39 | Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420. ( Banerjee, SK; Hashmi, M; Huang, CH; Leblanc, M; Mehta, S; Moon, J; Rinehart, E; Urba, SG; Williamson, S; Wolf, GT, 2013) |
| "Head and neck cancer (HNC) is the fifth most common cancer in the world." | 1.35 | Promising newer molecular-targeted therapies in head and neck cancer. ( Agulnik, M; Wang, LX, 2008) |
| "Carbogen breathing was started 5 minutes before and went on during each radiation fraction." | 1.29 | Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). ( Denekamp, J; Dennis, M; Franzén, L; Henriksson, R; Littbrand, B; Rojas, AM; Stratford, M; Zackrisson, B, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (17.95) | 18.2507 |
| 2000's | 11 (28.21) | 29.6817 |
| 2010's | 20 (51.28) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 1 |
| Jing, Y | 1 |
| Wang, S | 1 |
| Wu, Y | 1 |
| Sun, Y | 1 |
| Zhuang, J | 1 |
| Huang, X | 1 |
| Chen, S | 1 |
| Zhang, X | 1 |
| Song, Y | 1 |
| Hu, Q | 1 |
| Ni, Y | 1 |
| Mehta, S | 1 |
| Moon, J | 2 |
| Hashmi, M | 1 |
| Leblanc, M | 2 |
| Huang, CH | 2 |
| Rinehart, E | 1 |
| Wolf, GT | 2 |
| Urba, SG | 2 |
| Banerjee, SK | 1 |
| Williamson, S | 1 |
| Chevreau, C | 1 |
| Le Cesne, A | 1 |
| Ray-Coquard, I | 1 |
| Italiano, A | 1 |
| Cioffi, A | 1 |
| Isambert, N | 1 |
| Robin, YM | 1 |
| Fournier, C | 1 |
| Clisant, S | 1 |
| Chaigneau, L | 1 |
| Bay, JO | 1 |
| Bompas, E | 1 |
| Gauthier, E | 1 |
| Blay, JY | 1 |
| Penel, N | 1 |
| Laban, S | 2 |
| Steinmeister, L | 2 |
| Gleißner, L | 2 |
| Grob, TJ | 1 |
| Grénman, R | 2 |
| Petersen, C | 2 |
| Gal, A | 1 |
| Knecht, R | 2 |
| Dikomey, E | 2 |
| Kriegs, M | 2 |
| Bhatt, VR | 1 |
| Ganti, AK | 1 |
| Lalami, Y | 1 |
| Garcia, C | 1 |
| Flamen, P | 1 |
| Ameye, L | 1 |
| Paesmans, M | 1 |
| Awada, A | 1 |
| Lin, CL | 1 |
| Chiang, WF | 1 |
| Tung, CL | 1 |
| Hsieh, JL | 1 |
| Hsiao, JR | 1 |
| Huang, WT | 1 |
| Feng, LY | 1 |
| Chang, CH | 1 |
| Liu, SY | 1 |
| Tsao, CJ | 1 |
| Feng, YH | 1 |
| Terry, SY | 1 |
| Abiraj, K | 1 |
| Lok, J | 1 |
| Gerrits, D | 1 |
| Franssen, GM | 1 |
| Oyen, WJ | 2 |
| Boerman, OC | 1 |
| Gilbert, J | 1 |
| Schell, MJ | 1 |
| Zhao, X | 1 |
| Murphy, B | 1 |
| Tanvetyanon, T | 1 |
| Leon, ME | 1 |
| Neil Hayes, D | 1 |
| Haigentz, M | 1 |
| Saba, N | 1 |
| Nieva, J | 1 |
| Bishop, J | 1 |
| Sidransky, D | 1 |
| Ravi, R | 1 |
| Bedi, A | 1 |
| Chung, CH | 1 |
| Aderhold, C | 1 |
| Faber, A | 1 |
| Umbreit, C | 1 |
| Birk, R | 1 |
| Weiss, C | 1 |
| Sommer, JU | 1 |
| Hörmann, K | 1 |
| Schultz, JD | 1 |
| Möckelmann, N | 1 |
| Rieckmann, T | 1 |
| Busch, CJ | 1 |
| Becker, B | 1 |
| Hoffer, K | 1 |
| Omniczynski, M | 1 |
| Rothkamm, K | 1 |
| Janssens, GO | 1 |
| Langendijk, JA | 1 |
| Terhaard, CH | 1 |
| Doornaert, PA | 1 |
| van den Ende, P | 1 |
| de Jong, MA | 1 |
| Takes, RP | 1 |
| Span, PN | 1 |
| Kaanders, JH | 9 |
| Roh, JL | 1 |
| Kim, EH | 1 |
| Jang, H | 1 |
| Shin, D | 1 |
| Affolter, A | 1 |
| Samosny, G | 1 |
| Heimes, AS | 1 |
| Schneider, J | 1 |
| Weichert, W | 1 |
| Stenzinger, A | 1 |
| Sommer, K | 1 |
| Jensen, A | 1 |
| Mayer, A | 1 |
| Brenner, W | 1 |
| Mann, WJ | 1 |
| Brieger, J | 1 |
| Wang, LX | 1 |
| Agulnik, M | 2 |
| Donghi, D | 1 |
| Dummer, R | 1 |
| Cozzio, A | 1 |
| Williamson, SK | 1 |
| Guaglianone, PP | 1 |
| Kruser, TJ | 1 |
| Wheeler, DL | 1 |
| Armstrong, EA | 1 |
| Iida, M | 1 |
| Kozak, KR | 1 |
| van der Kogel, AJ | 8 |
| Bussink, J | 4 |
| Coxon, A | 1 |
| Polverino, A | 1 |
| Harari, PM | 1 |
| Leroux, C | 1 |
| Vauléon, E | 1 |
| Pracht, M | 1 |
| Zoheir, Y | 1 |
| Boucher, E | 1 |
| Audrain, O | 1 |
| Raoul, JL | 1 |
| Egberts, F | 1 |
| Gutzmer, R | 1 |
| Ugurel, S | 1 |
| Becker, JC | 1 |
| Trefzer, U | 1 |
| Degen, A | 1 |
| Schenck, F | 1 |
| Frey, L | 1 |
| Wilhelm, T | 1 |
| Hassel, JC | 1 |
| Schadendorf, D | 1 |
| Livingstone, E | 1 |
| Mauch, C | 1 |
| Garbe, C | 1 |
| Berking, C | 1 |
| Rass, K | 1 |
| Mohr, P | 1 |
| Kaehler, KC | 1 |
| Weichenthal, M | 1 |
| Hauschild, A | 1 |
| Tamiya, H | 1 |
| Kamo, R | 1 |
| Kumei, A | 1 |
| Yanagihara, S | 1 |
| Ishii, M | 1 |
| Kobayashi, H | 1 |
| Ono, S | 1 |
| Tanioka, M | 1 |
| Fujisawa, A | 1 |
| Tanizaki, H | 1 |
| Miyachi, Y | 1 |
| Matsumura, Y | 1 |
| Wijffels, KI | 2 |
| Marres, HA | 4 |
| Ljungkvist, AS | 1 |
| Pop, LA | 4 |
| van den Hoogen, FJ | 3 |
| de Wilde, PC | 2 |
| Raleigh, JA | 1 |
| Glaholm, J | 1 |
| Watkinson, JC | 1 |
| Hoogsteen, IJ | 1 |
| Merkx, MA | 3 |
| Jonathan, RA | 1 |
| Peeters, W | 1 |
| Oosterwijk, E | 1 |
| de Geus-Oei, LF | 1 |
| Corstens, FH | 1 |
| Hampton, T | 1 |
| Elser, C | 1 |
| Siu, LL | 1 |
| Winquist, E | 1 |
| Pond, GR | 1 |
| Chin, SF | 1 |
| Francis, P | 1 |
| Cheiken, R | 1 |
| Elting, J | 1 |
| McNabola, A | 1 |
| Wilkie, D | 1 |
| Petrenciuc, O | 1 |
| Chen, EX | 1 |
| Smid, L | 1 |
| Lesnicar, H | 1 |
| Zakotnik, B | 1 |
| Soba, E | 1 |
| Budihna, M | 1 |
| Furlan, L | 1 |
| Zargi, M | 1 |
| Rudolf, Z | 1 |
| Zackrisson, B | 1 |
| Franzén, L | 1 |
| Henriksson, R | 1 |
| Littbrand, B | 1 |
| Stratford, M | 1 |
| Dennis, M | 1 |
| Rojas, AM | 2 |
| Denekamp, J | 5 |
| Stratford, MR | 3 |
| Liefers, J | 1 |
| Dennis, MF | 3 |
| van Daal, WA | 1 |
| Rojas, A | 3 |
| Fowler, JF | 1 |
| Saunders, MI | 1 |
| Hoskin, PJ | 1 |
| Pigott, K | 1 |
| Powell, ME | 1 |
| Goodchild, K | 1 |
| Dische, S | 1 |
| Bernier, J | 2 |
| Bieri, S | 1 |
| Hagen, F | 1 |
| Kocagöncü, O | 1 |
| Bolla, M | 1 |
| Minatel, E | 1 |
| Horiot, J | 1 |
| Hamers, H | 1 |
| Antognoni, P | 1 |
| Dahl, O | 1 |
| Richaud, P | 1 |
| van Glabbeke, M | 1 |
| Piérart, M | 1 |
| Bruaset, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.[NCT00147732] | Phase 3 | 345 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Head and Neck Neoplasms
| Article | Year |
|---|---|
ARCON: a novel biology-based approach in radiotherapy.
Topics: Animals; Carbon Dioxide; Carcinoma; Cell Cycle; Cell Hypoxia; Clinical Trials as Topic; Dose Fractio | 2002 |
ARCON--current status: summary of a workshop on preclinical and clinical studies.
Topics: Animals; Carbon Dioxide; Cell Division; Cell Hypoxia; Head and Neck Neoplasms; Humans; Neoplasm Recu | 1997 |
14 trials available for niacinamide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration | 2013 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head a | 2016 |
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neopl | 2015 |
Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Female; Follow-Up Studies; Head and Neck Neoplasms; | 2016 |
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; | 2010 |
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic | 2002 |
Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Carcinoma, Squamous Cell | 2006 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression | 2007 |
Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer--preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ch | 1995 |
Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study.
Topics: Administration, Oral; Aerosols; Antiemetics; Carbon Dioxide; Disease-Free Survival; Dose Fractionati | 1997 |
Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer.
Topics: Administration, Oral; Area Under Curve; Carbon Dioxide; Carcinoma; Carcinoma, Non-Small-Cell Lung; C | 1998 |
ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
Topics: Adult; Aged; Carbon Dioxide; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Head and Neck | 2000 |
ARCON: experience in 215 patients with advanced head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Dose Fractionation, Radiation; Feasibility Studies; | 2002 |
23 other studies available for niacinamide and Head and Neck Neoplasms
| Article | Year |
|---|---|
Identification of Biological Functions and Prognostic Value of NNMT in Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Niacinamide; Nicotinamid | 2022 |
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clin | 2013 |
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide | 2013 |
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Pheny | 2014 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulati | 2015 |
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizu | 2014 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulati | 2015 |
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Prolifer | 2016 |
Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Aspirin; Cell Line, Tumor; Cisplat | 2017 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combin | 2017 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2008 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; He | 2010 |
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combinatio | 2010 |
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male | 2011 |
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinam | 2012 |
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Hu | 2012 |
Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Cell Hypoxia; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractio | 2003 |
The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbon Dioxide; Carbonic Anhy | 2006 |
Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer.
Topics: Aged; Aged, 80 and over; Carbon; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Ma | 2006 |
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; | 2007 |
Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON).
Topics: Administration, Inhalation; Aged; Carbon Dioxide; Carcinoma, Squamous Cell; Head and Neck Neoplasms; | 1994 |
Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; H | 1997 |
Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide.
Topics: Carbon Dioxide; Cell Division; Cell Hypoxia; Head and Neck Neoplasms; Humans; Niacinamide; Oxygen; R | 1999 |